<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45379">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107326</url>
  </required_header>
  <id_info>
    <org_study_id>CER13-272</org_study_id>
    <nct_id>NCT02107326</nct_id>
  </id_info>
  <brief_title>Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes</brief_title>
  <official_title>Webdia Study: Use of Smartphones to Improve Diabetes Control and Quality of Life in Children With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philippe Klee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of a software for smartphones and
      tablets on type 1 diabetes control and quality of life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis underlying this project, is that most calculations necessary for flexible
      intensive insulin therapy for type 1 diabetes in children can be performed using software
      installed on a smartphone or tablet that nowadays is carried by most parents and children.
      Smartphones and tablets can easily communicate with each other and with a desktop computer
      via the Internet, thereby permitting the exchange of information such as blood glucose
      values or types of meals among family members and physicians. Finally, software collecting
      blood glucose values and merging values obtained on different devices easily permits
      reviewing these values by the patient and sending them to the physician's office, thereby
      avoiding consultations during which no blood glucose values are brought by the patient.

      We hypothesize that the Webdia software, that will be tested in this randomized crossover
      study, will increase treatment compliance and therefore will improve diabetes
      self-management. We believe, the software will facilitate the adaptation of insulin schemes
      by physicians and therefore will lead to improved HbA1C values. We also think that this
      software will improve the patient's quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect of Webdia Software use on HbA1C</measure>
    <time_frame>0, 3, 6 and 9 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Webdia Software use on quality of life</measure>
    <time_frame>0, 3, 6 and 9 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life assessment by the use of the Diabetes Quality of Life for Youths (DQOLY) questionnaire published by Ingersoll et al. 1991.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Webdia Software use on the incidence of hypoglycaemic events</measure>
    <time_frame>During 2 weeks at the end of the 3-months period of Webdia Software use</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Quality of Life</condition>
  <condition>Hypoglycaemia</condition>
  <arm_group>
    <arm_group_label>Webdia Software use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Webdia Software during 3 months by the patient. Monthly review of blood glucose values by the medical team and automatic adjustment of insulin doses by the team.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No use of the software. No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Webdia Software</intervention_name>
    <arm_group_label>Webdia Software use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 10 - 18 years

          -  Type 1 diabetes mellitus with positive auto-antibodies against Islet Antigen (IA) 2,
             insulin, islets, Glutamic Acid Decarboxylase (GAD) 65 or Zink

          -  Disease duration equal or more than 6 months

          -  Treatment by subcutaneous insulin: by multiple daily injections of pump therapy

        Exclusion Criteria:

          -  Previous use of Webdia Software

          -  Absence of hardware necessary to install the Webdia Software
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Klee, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Klee, MD-PhD</last_name>
    <phone>+41 79 55 33 476</phone>
    <email>philippe.klee@hcuge.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie M Schwitzgebel, MD</last_name>
    <phone>+41 22 372 45 92</phone>
    <email>valerie.schwitzgebel@hcuge.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Geneva</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Klee, MD-PhD</last_name>
      <phone>+41 79 55 33 476</phone>
      <email>philippe.klee@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Valérie M Schwitzgebel, MD</last_name>
      <phone>+41 22 372 45 92</phone>
      <email>valerie.schwitzgebel@hcuge.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Klee, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.webdia.ch</url>
    <description>Homepage of the Webdia Software being tested in this study</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>April 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Philippe Klee</investigator_full_name>
    <investigator_title>MD-PhD</investigator_title>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>HbA1C</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Hypoglycaemia</keyword>
  <keyword>Self-management</keyword>
  <keyword>Telemedicine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
